文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

目标导向治疗对创伤性脑损伤患者发病率与死亡率的影响:孕酮治疗创伤性脑损伤III期临床试验结果

The Effect of Goal-Directed Therapy on Patient Morbidity and Mortality After Traumatic Brain Injury: Results From the Progesterone for the Treatment of Traumatic Brain Injury III Clinical Trial.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论在孕酮治疗创伤性脑损伤III期试验的882例中重度创伤性脑损伤患者中,目标导向治疗的多项生理指标偏离与6个月死亡率升高相关,提示有效实施目标导向治疗可能改善结局。

该研究为孕酮治疗创伤性脑损伤III期临床试验的计划性二次分析,纳入42个创伤中心、伤后4小时内、格拉斯哥昏迷评分4-12分的非穿透性创伤性脑损伤患者882例。研究预先定义生理目标以标准化治疗,每小时采集生理数据,将偏离正常范围定义为「 transgressions 」,采用逻辑回归分析偏离与6个月死亡率和格拉斯哥结局扩展量表的关系。结果显示全队列死亡率为12.5%,较长时间处于血红蛋白<8 g/dL、INR>1.4、血糖>180 mg/dL、收缩压<90 mm Hg的偏离状态与死亡率升高相关。作者认为,有效的目标导向治疗可能为改善创伤性脑损伤患者结局提供机会。

要点

  • 全队列882例中重度创伤性脑损伤患者6个月死亡率为12.5%。
  • 全队列中,较长时间处于血红蛋白<8 gm/dL(p=0.0006)、INR>1.4(p<0.0001)、血糖>180 mg/dL(p=0.0003)、收缩压<90 mm Hg(p<0.0001)的偏离状态与死亡率升高相关。
  • 颅内压监测亚组中,较长时间处于颅内压≥20 mm Hg(p<0.0001)、血糖>180 mg/dL(p=0.0293)、血红蛋白<8 gm/dL(p=0.0220)、收缩压<90 mm Hg(p=0.0114)的偏离状态与死亡率升高相关。
  • 与死亡率呈负相关的协变量包括:单次平均动脉压<65 mm Hg(p=0.0051)或收缩压>180 mm Hg(p=0.0002)。
  • 作者认为,有效的目标导向治疗在创伤性脑损伤中可能提供改善患者结局的机会。

适用人群与场景

  • 纳入标准:非穿透性创伤性脑损伤,格拉斯哥昏迷评分4-12分,伤后4小时内入组,共882例,来自42个创伤中心。
  • 研究场景:参与孕酮治疗创伤性脑损伤III期临床试验的42个创伤中心。

诊断标准与关键阈值

  • 生理目标预先定义以标准化治疗,生理数据每小时采集,实验室数据按当地ICU方案采集且至少每日一次。
  • 生理偏离预先定义为显著偏离目标导向治疗正常范围,目标导向治疗未达标的每个小时分类为一次「偏离」。

红旗征与不能漏的情况

  • 较长时间处于血红蛋白<8 gm/dL与死亡率升高相关(全队列p=0.0006)。
  • 较长时间处于INR>1.4与死亡率升高相关(全队列p<0.0001)。
  • 较长时间处于血糖>180 mg/dL与死亡率升高相关(全队列p=0.0003;颅内压监测亚组p=0.0293)。
  • 较长时间处于收缩压<90 mm Hg与死亡率升高相关(全队列p<0.0001;颅内压监测亚组p=0.0114)。
  • 颅内压监测亚组中,较长时间处于颅内压≥20 mm Hg与死亡率升高相关(p<0.0001)。

研究设计与关键结果

  • 研究类型:孕酮治疗创伤性脑损伤III期临床试验的计划性二次分析,该试验为大型前瞻性多中心临床试验,共42个创伤中心参与。
  • 样本量:882例患者,伤后4小时内入组,格拉斯哥昏迷评分4-12分,非穿透性创伤性脑损伤。
  • 主要结局:6个月死亡率为12.5%。
  • 全队列中,较长时间处于血红蛋白<8 gm/dL(p=0.0006)、INR>1.4(p<0.0001)、血糖>180 mg/dL(p=0.0003)、收缩压<90 mm Hg(p<0.0001)的偏离状态与死亡率升高相关。
  • 颅内压监测亚组中,较长时间处于颅内压≥20 mm Hg(p<0.0001)、血糖>180 mg/dL(p=0.0293)、血红蛋白<8 gm/dL(p=0.0220)、收缩压<90 mm Hg(p=0.0114)的偏离状态与死亡率升高相关。
  • 与死亡率呈负相关的协变量包括:单次平均动脉压<65 mm Hg(p=0.0051)或收缩压>180 mm Hg(p=0.0002)。

证据类型、等级与局限

  • 证据类型:计划性二次分析,数据来自大型前瞻性多中心临床试验(孕酮治疗创伤性脑损伤III期)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,有效的目标导向治疗在创伤性脑损伤中可能提供改善患者结局的机会。
  • 原文未据此给出推荐。

指南或共识出处

  • 孕酮治疗创伤性脑损伤III期临床试验(Progesterone for the Treatment of Traumatic Brain Injury III)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To estimate the impact of goal-directed therapy on outcome after traumatic brain injury, our team applied goal-directed therapy to standardize care in patients with moderate to severe traumatic brain injury, who were enrolled in a large multicenter clinical trial.

DESIGN: Planned secondary analysis of data from Progesterone for the Treatment of Traumatic Brain Injury III, a large, prospective, multicenter clinical trial.

SETTING: Forty-two trauma centers within the Neurologic Emergencies Treatment Trials network.

PATIENTS: Eight-hundred eighty-two patients were enrolled within 4 hours of injury after nonpenetrating traumatic brain injury characterized by Glasgow Coma Scale score of 4-12.

MEASUREMENTS AND MAIN RESULTS: Physiologic goals were defined a priori in order to standardize care across 42 sites participating in Progesterone for the Treatment of Traumatic Brain Injury III. Physiologic data collection occurred hourly; laboratory data were collected according to local ICU protocols and at a minimum of once per day. Physiologic transgressions were predefined as substantial deviations from the normal range of goal-directed therapy. Each hour where goal-directed therapy was not achieved was classified as a "transgression." Data were adjudicated electronically and via expert review. Six-month outcomes included mortality and the stratified dichotomy of the Glasgow Outcome Scale-Extended. For each variable, the association between outcome and either: 1) the occurrence of a transgression or 2) the proportion of time spent in transgression was estimated via logistic regression model.

RESULTS: For the 882 patients enrolled in Progesterone for the Treatment of Traumatic Brain Injury III, mortality was 12.5%. Prolonged time spent in transgression was associated with increased mortality in the full cohort for hemoglobin less than 8 gm/dL (p = 0.0006), international normalized ratio greater than 1.4 (p < 0.0001), glucose greater than 180 mg/dL (p = 0.0003), and systolic blood pressure less than 90 mm Hg (p < 0.0001). In the patient subgroup with intracranial pressure monitoring, prolonged time spent in transgression was associated with increased mortality for intracranial pressure greater than or equal to 20 mm Hg (p < 0.0001), glucose greater than 180 mg/dL (p = 0.0293), hemoglobin less than 8 gm/dL (p = 0.0220), or systolic blood pressure less than 90 mm Hg (p = 0.0114). Covariates inversely related to mortality included: a single occurrence of mean arterial pressure less than 65 mm Hg (p = 0.0051) or systolic blood pressure greater than 180 mm Hg (p = 0.0002).

CONCLUSIONS: The Progesterone for the Treatment of Traumatic Brain Injury III clinical trial rigorously monitored compliance with goal-directed therapy after traumatic brain injury. Multiple significant associations between physiologic transgressions, morbidity, and mortality were observed. These data suggest that effective goal-directed therapy in traumatic brain injury may provide an opportunity to improve patient outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Merck LH, Yeatts SD, Silbergleit R, et al. The Effect of Goal-Directed Therapy on Patient Morbidity and Mortality After Traumatic Brain Injury: Results From the Progesterone for the Treatment of Traumatic Brain Injury III Clinical Trial. Crit Care Med. 2019. PMID: 30730438. doi:10.1097/CCM.0000000000003680

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。